Two multicenter, randomized, single-blind, single-dose, crossover studies of specific sensory attributes of budesonide aqueous nasal spray and fluticasone propionate nasal spray

Shah, Shailen; Miller, Christopher J.; Pethick, Ned; Uryniak, Tom; Jones, Martin; O'Dowd, L.

doi:10.1016/s0149-2918(03)80213-8

Cited by 30 publications

(34 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because the MFNS has a larger volume, it may linger longer despite the washout and may lead to blunting of the perception of the second spray (FFNS). This finding was consistent with the study by Shah et al , 16 which showed that patients randomized to receive budesonide aqueous nasal spray before FPNS had a stronger preference for budesonide aqueous nasal spray than those who received budesonide aqueous nasal spray second.…”

Section: Discussionsupporting

confidence: 92%

A Patient Preference Study that Evaluated Fluticasone Furoate and Mometasone Furoate Nasal Sprays for Allergic Rhinitis

Yáñez¹,

Dimitroff

Bremner

et al. 2016

Allergy�Rhinol (Providence)

View full text Add to dashboard Cite

Background:Corticosteroid nasal sprays are the mainstay of treatment for allergic rhinitis. These sprays have sensory attributes such as scent and/or odor, taste and aftertaste, and run down the throat and/or the nose, which, when unpleasant, can affect patient preference for, and compliance with, treatment.Objective:This study examined patient preference for fluticasone furoate nasal spray (FFNS) or mometasone furoate nasal spray (MFNS) based on their sensory attributes after administration in patients with allergic rhinitis.Methods:This was a multicenter, randomized, double-blind, cross-over study. Patient preferences were determined by using three questionnaires (Overall Preference, Immediate Attributes, and Delayed Attributes).Results:Overall, 56% of patients stated a preference for FFNS versus 32% for MFNS (p < 0.001); the remaining 12% stated no preference. More patients stated a preference for FFNS versus MFNS for the attributes of “less drip down the throat” (p < 0.001), “less run out of the nose” (p < 0.05), “more soothing” (p < 0.05), and “less irritating” (p < 0.001). More patients responded in favor of FFNS versus MFNS for the immediate attributes, “run down the throat” (p < 0.001), and “run out of the nose” (p < 0.001), and, in the delayed attributes, “run down the throat” (p < 0.001), “run out of the nose” (p < 0.01), “presence of aftertaste” (p < 0.01), and “no nasal irritation” (p < 0.001).Conclusion:Patients with allergic rhinitis preferred FFNS versus MFNS overall and based on a number of individual attributes, including “less drip down the throat,” “less run out of the nose,” and “less irritating.” Greater preference may improve patient adherence and thereby improve symptom management of the patient's allergic rhinitis.

show abstract

Section: Discussionsupporting

confidence: 92%

A Patient Preference Study that Evaluated Fluticasone Furoate and Mometasone Furoate Nasal Sprays for Allergic Rhinitis

Yáñez¹,

Dimitroff

Bremner

et al. 2016

Allergy�Rhinol (Providence)

View full text Add to dashboard Cite

show abstract

“…10 Questionnaires using these attributes, such as the Sensory Perception Questionnaire, have shown good preliminary construct and content validity, and they have been used successfully in clinical trials of INSs. 9,10 By including different amounts of money as an attribute in a conjoint analysis study design, estimates of willingness to pay for changes in the levels of the attributes of importance can be derived. 21 Therefore, a seventh attribute, monthly copayment amount, was added to determine how much patients would trade-off sensory attributes for a monthly cost burden.…”

Section: Discrete Choice Experiments Surveymentioning

confidence: 99%

“…Patient preferences were rated on a 14-item nasal spray evaluation questionnaire, which evaluates the acceptability of the drug and associated sensory perceptions immediately (10 items) and 2 minutes after (4 items) drug administration, using a 100-point rating scale. Both Bachert and El-Akkad 7 and Shah et al 9 assessed patients' perceptions of and preferences for certain INS sensory attributes, but they did not assess the strength of patient preferences in terms of their willingness to pay for an INS with the sensory attributes they prefer or would like to avoid.…”

mentioning

confidence: 99%

Willingness to Pay for Sensory Attributes of Intranasal Corticosteroids Among Patients With Allergic Rhinitis

Mahadevia¹,

Shah²,

Mannix³

et al. 2006

JMCP

Self Cite

View full text Add to dashboard Cite

“…1 Studies show that when adult patients with AR are able to compare products directly, they can distinguish among the sensory attributes of INS sprays, such as odor and taste, and they express definite preferences. [53][54][55][56] In a double-blinded crossover study, 94 patients with AR received single doses, 30 minutes apart, of TANS, FPNS, and BDP nasal spray, in random order. 53 Disregarding BDP, which is not approved for once-daily use, the results showed that patients rated TANS as significantly better than FPNS with respect to odor (p Ͻ 0.001), odor strength (p Ͻ 0.001), and taste (p Ͻ 0.04).…”

Section: Patient Preference and Adherencementioning

confidence: 99%

“…56 In one of the studies, 181 patients used the recommended once-daily starting doses of both BANS (one 32-g spray per nostril) and FPNS (two 50-g sprays per nostril). In the second study, 190 patients used the same dose of BANS (one 32-g spray per nostril) as the first study, and half the recommended dose of FPNS (one 50-g spray per nostril), to balance the number of actuations administered for each drug.…”

Section: Choosing An Allergic Rhinitis Therapy For Childrenmentioning

confidence: 99%

Allergic Rhinitis in Children: Selecting an Intranasal Corticosteroid

Murphy¹

2005

Pediatric Asthma, Allergy & Immunology

View full text Add to dashboard Cite

Allergic rhinitis affects up to 40% of children in the United States. Proper management of this disease is important for controlling symptoms, improving quality of life, and preventing the development or exacerbation of comorbid diseases such as asthma, sinusitis, otitis media, and respiratory infections. Intranasal corticosteroids (INSs) are recognized as the most effective medication class for controlling allergic rhinitis symptoms and are recommended by guidelines as first-line treatment for moderate to severe cases of allergic rhinitis in patients of all ages. Four once-daily, aqueous formulations of INSs are available in the United States for pediatric patients: budesonide aqueous nasal spray (BANS), fluticasone propionate nasal spray (FPNS), mometasone furoate nasal spray (MFNS), and triamcinolone acetonide aqueous nasal spray (TANS). The results of comparative studies of these INSs show that all four appear to be similar in efficacy and tolerability. The sensory attributes of these INSs do differ and these differences may play a role in the choice of an INS for each patient. Based on studies in adults, patient preference was found to be greater for the sensory attributes of BANS and TANS than for those of FPNS and MFNS, although a number of patients still showed a preference for the attributes of FPNS and MFNS. Similar studies of INS sensory attributes have not been conducted in children. Prescribing the INS with sensory attributes most pleasing to the individual patient may be important in improving patient acceptance of and satisfaction with treatment and perhaps lead to better adherence with therapy. (Pediatr Asthma Allergy Immunol 2005; 18[4]:216-229.)Adapted from Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma.

show abstract

Two multicenter, randomized, single-blind, single-dose, crossover studies of specific sensory attributes of budesonide aqueous nasal spray and fluticasone propionate nasal spray

Cited by 30 publications

References 17 publications

A Patient Preference Study that Evaluated Fluticasone Furoate and Mometasone Furoate Nasal Sprays for Allergic Rhinitis

A Patient Preference Study that Evaluated Fluticasone Furoate and Mometasone Furoate Nasal Sprays for Allergic Rhinitis

Willingness to Pay for Sensory Attributes of Intranasal Corticosteroids Among Patients With Allergic Rhinitis

Allergic Rhinitis in Children: Selecting an Intranasal Corticosteroid

Contact Info

Product

Resources

About